- Home
- HRTX vs CATX Comparison
HRTX vs CATX Comparison
Compare HRTX & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- CATX
- Stock Information
- Founded
- HRTX 1983
- CATX 1983
- Country
- HRTX United States
- CATX United States
- Employees
- HRTX N/A
- CATX N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- HRTX Health Care
- CATX Health Care
- Exchange
- HRTX Nasdaq
- CATX Nasdaq
- Market Cap
- HRTX 203.5M
- CATX 239.0M
- IPO Year
- HRTX 1987
- CATX N/A
- Fundamental
- Price
- HRTX $1.11
- CATX $2.29
- Analyst Decision
- HRTX Strong Buy
- CATX Strong Buy
- Analyst Count
- HRTX 2
- CATX 10
- Target Price
- HRTX $4.50
- CATX $12.20
- AVG Volume (30 Days)
- HRTX 2.1M
- CATX 1.8M
- Earning Date
- HRTX 11-04-2025
- CATX 11-10-2025
- Dividend Yield
- HRTX N/A
- CATX N/A
- EPS Growth
- HRTX N/A
- CATX N/A
- EPS
- HRTX N/A
- CATX N/A
- Revenue
- HRTX $155,097,000.00
- CATX $1,075,000.00
- Revenue This Year
- HRTX $10.62
- CATX N/A
- Revenue Next Year
- HRTX $12.99
- CATX N/A
- P/E Ratio
- HRTX N/A
- CATX N/A
- Revenue Growth
- HRTX 12.60
- CATX N/A
- 52 Week Low
- HRTX $1.04
- CATX $1.60
- 52 Week High
- HRTX $2.68
- CATX $7.95
- Technical
- Relative Strength Index (RSI)
- HRTX 39.29
- CATX 36.33
- Support Level
- HRTX $1.09
- CATX $2.00
- Resistance Level
- HRTX $1.14
- CATX $2.31
- Average True Range (ATR)
- HRTX 0.07
- CATX 0.18
- MACD
- HRTX 0.00
- CATX 0.01
- Stochastic Oscillator
- HRTX 27.08
- CATX 34.61
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.